TY - JOUR
T1 - A comparison of the oxytocin and vasopressin responses to the 5-HT(1A) agonist and potential anxiolytic drug alnespirone (S-20499)
AU - Van De Kar, Louis D.
AU - Levy, Andrew D.
AU - Li, Qian
AU - Brownfield, Mark S.
N1 - Funding Information:
This research was supported in part by United States Public Health Service Grants MH45812 (L.D.V.d.K. and M.S.B.) and NS34153 (L.D.V.d.K.), and by the Institut de Recherches Internationales Servier (L.D.V.d.K.).
PY - 1998/6
Y1 - 1998/6
N2 - The effect of the serotonin(1A) (5-HT(1A)) agonist alnespirone (S- 20499) on the secretion of both oxytocin and vasopressin was examined in the same conscious, unrestrained male rats. The dose-response and time-course effects on the secretion of oxytocin and vasopressin revealed that alnespirone stimulated oxytocin in a dose-dependent manner, but did not increase vasopressin secretion. Time of maximal effect following injection of alnespirone (5 mg/kg, IP) was as early as 15 min postinjection, with significant stimulation persisting for 30 min. Pretreatment with a low dose of the 5-HT(1A)/β-adrenoceptor antagonist (-)-pindolol (0.3 mg/kg, SC), 30 min prior to injection of alnespirone (0, 2, 5, and 10 mg/kg, IP) shifted the dose-response curve to the right and inhibited the effect of alnespirone on plasma oxytocin concentration. Furthermore, pretreatment with a low or a high dose of the 5-HT(1A/2A)/dopamine D2 antagonist spiperone (0.01 or 3 mg/kg, SC) dose dependently shifted the alnespirone dose-response curve effect of alnespirone to the right. None of these drugs, alone or in combination, altered plasma vasopressin levels. These studies suggest that 5-HT(1A) receptor mechanisms mediate the effect of alnespirone on the secretion of oxytocin. Furthermore, these studies suggest that 5-HT(1A) receptor mechanisms do not participate in the serotonergic regulation of vasopressin secretion.
AB - The effect of the serotonin(1A) (5-HT(1A)) agonist alnespirone (S- 20499) on the secretion of both oxytocin and vasopressin was examined in the same conscious, unrestrained male rats. The dose-response and time-course effects on the secretion of oxytocin and vasopressin revealed that alnespirone stimulated oxytocin in a dose-dependent manner, but did not increase vasopressin secretion. Time of maximal effect following injection of alnespirone (5 mg/kg, IP) was as early as 15 min postinjection, with significant stimulation persisting for 30 min. Pretreatment with a low dose of the 5-HT(1A)/β-adrenoceptor antagonist (-)-pindolol (0.3 mg/kg, SC), 30 min prior to injection of alnespirone (0, 2, 5, and 10 mg/kg, IP) shifted the dose-response curve to the right and inhibited the effect of alnespirone on plasma oxytocin concentration. Furthermore, pretreatment with a low or a high dose of the 5-HT(1A/2A)/dopamine D2 antagonist spiperone (0.01 or 3 mg/kg, SC) dose dependently shifted the alnespirone dose-response curve effect of alnespirone to the right. None of these drugs, alone or in combination, altered plasma vasopressin levels. These studies suggest that 5-HT(1A) receptor mechanisms mediate the effect of alnespirone on the secretion of oxytocin. Furthermore, these studies suggest that 5-HT(1A) receptor mechanisms do not participate in the serotonergic regulation of vasopressin secretion.
KW - 5-HT(1A) antagonist
KW - Dose-response
KW - Hormone
KW - Hypothalamus
KW - Neuroendocrine
KW - Paraventricular nucleus
KW - Receptor
KW - Secretion
KW - Serotonin
KW - Time course
UR - http://www.scopus.com/inward/record.url?scp=0031827433&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031827433&partnerID=8YFLogxK
U2 - 10.1016/S0091-3057(98)00025-2
DO - 10.1016/S0091-3057(98)00025-2
M3 - Article
C2 - 9678651
AN - SCOPUS:0031827433
SN - 0091-3057
VL - 60
SP - 677
EP - 683
JO - Pharmacology Biochemistry and Behavior
JF - Pharmacology Biochemistry and Behavior
IS - 3
ER -